Bayer clinches Monsanto with better bid

NEW YORK/FRANKFURT - German drug and crop chemical maker Bayer clinched a US$66 billion takeover of US seeds company Monsanto on Wednesday, ending months of wrangling with a third sweetened offer that marks the largest all-cash deal on record.The US$128-a-share deal, up from Bayer's previous offer of $127.50 a share, has emerged as the signature deal in a consolidation race that has roiled the agribusiness sector in recent years, due to shifting weather patterns, intense competition in grain exports and a souring global farm economy." Bayer's competitors are merging, so not doing this deal would mean having a competitive disadvantage," said fund manager Markus Manns of Union Investment, one of Bayer's top 12 investors.Grain prices are hovering near their lowest levels in years amid a global supply glut, and farm incomes have plunged.But the proposed merger will likely face an intense and lengthy regulatory process in the United States, Canada, Brazil, the European Union and elsewhere. Hugh Grant, Monsanto's chief executive, said Wednesday the companies will need to file in about 30 jurisdictions for the merger.Competition authorities are likely to scrutinise the tie-up closely, and some of Bayer's own shareholders have been highly critical of a takeover that they say risks overpaying and neglecting the company's pharmaceutical business.If the deal closes, it will create a company commanding more than a quarter of the combined world market for seeds and pesticides in the fast-consolidating farm supplies industry.What the newly-formed company would be named is unclear.The transaction includes a US$2-billion break-up fee that Bayer will pay to Monsanto should it fail to get regulatory clearance. Bayer expects the deal to close by the end of 2017. - Nampa/Reuters

Bayer clinches Monsanto with better bid

Kommentaar

Republikein 2025-06-19

Meld asseblief aan om kommentaar te lewer

Bayer clinches Monsanto with better bid

Kommentaar

Republikein 2025-06-19

Meld asseblief aan om kommentaar te lewer

MELD AAN

Advertensie